阿米奥达龙联合晶体的理性设计:一种结合计算预测,降水抑制聚合物和配方优化的协同策略
Rahul Jha1, Smit Patel1, Arzoo Sekhani1
1Maliba Pharmacy College, Uka Tarsadia University, Tarsadi, Bardoli, Gujarat, 394350, India.
AAPS PharmSciTech
|March 3, 2026
概括
这项研究开发了阿米奥达龙化 (AMH) 共同晶体,以改善药物的溶解性和溶解性. 由此产生的片剂显示了药物释放的增强,为治疗心律失常提供了有前途的配方.
科学领域:
- 制药科学 制药科学
- 药物运输 药物运输 药物运输
- 材料科学 材料科学 材料科学
背景情况:
- 阿米奥达龙化 (AMH) 具有较差的水溶性,限制了其生物可用性和治疗疗效.
- 同结晶是一种可行的策略,可以提高生物制药分类系统II类药物的溶解性和溶解性,如AMH.
研究的目的:
- 开发一种具有更好的溶解性和溶解性的AMH联合晶体即时释放片剂配方.
- 调查前者选择和优化药片配方,以提高药物释放和稳定性.
主要方法:
- 使用热力学计算的共同晶体选 (过度,汉森溶解度参数).
- 通过液体辅助研磨合成AMH联合晶体 (阿米奥达龙-酸,阿米奥达龙-酸).
- 使用PXRD,DSC,FTIR和SEM进行表征;可溶性研究;聚合物选;使用实验设计优化药片配方;稳定性测试.
主要成果:
- 与纯AMH相比,阿米奥达龙-酸联合晶体显示出明显增强的溶解性.
- 聚乙烯甘醇4000被确定为控制相变化的最佳聚合物.
- 优化的药片在20分钟内实现了>90%的AMH释放,超过了市场上销售的产品.
结论:
- 亚米合结晶有效地提高了溶解性和溶解特性.
- 开发的即时释放药片配方强大,稳定,并显示在治疗心律失常时具有临床应用潜力.
相关概念视频
Precipitation Processes
5.0K
The experimental conditions in a gravimetric analysis should be optimized to maximize the particle size and purity of the obtained precipitate. Ideally, the concentration of the precipitating reagent should be low with effective stirring to maintain low relative supersaturation for the growth of large crystals. In homogeneous precipitation, the precipitant is slowly generated by a chemical reaction in the solution to avoid local reagent excesses. For example, urea decomposes gradually to...
5.0K
Colloidal precipitates
5.7K
The high insolubility of some precipitates can result in an unfavorable relative supersaturation. This can lead to colloidal particles with a large surface-to-mass ratio, where adsorption is promoted. For instance, in the precipitation of silver chloride, silver ions are adsorbed on the surface of the colloidal particles, forming a primary layer. This layer attracts ions of opposite charge (such as nitrate ions), forming a diffuse secondary layer of adsorbed ions. This electric double layer...
5.7K
Structure-Activity Relationships and Drug Design
1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
883
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
883
Biopharmaceutical Factors Influencing Drug Product Design: Overview
547
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
547
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226


